This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Kahn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahm, D. F.
Right arrow Articles by Kahn, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 267-274, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.267-274.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance

Daniel F. Sahm,1,* Ian A. Critchley,1 Laurie J. Kelly,1 James A. Karlowsky,1 David C. Mayfield,1 Clyde Thornsberry,2 Yolanda R. Mauriz,3 and James Kahn3

MRL, Herndon, Virginia 20171,1 MRL, Brentwood, Tennessee 37027,2 and Ortho-McNeil Pharmaceutical, Inc., Raritan, New Jersey 088693

Received 15 June 2000/Returned for modification 28 September 2000/Accepted 26 October 2000

Given the propensity for Enterobacteriaceae and clinically significant nonfermentative gram-negative bacilli to acquire antimicrobial resistance, consistent surveillance of the activities of agents commonly prescribed to treat infections arising from these organisms is imperative. This study determined the activities of two fluoroquinolones, levofloxacin and ciprofloxacin, and seven comparative agents against recent clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia using two surveillance strategies: 1) centralized in vitro susceptibility testing of isolates collected from 27 hospital laboratories across the United States and 2) analysis of data from The Surveillance Network Database-USA, an electronic surveillance network comprising more than 200 laboratories nationwide. Regardless of the surveillance method, Enterobacteriaceae, P. aeruginosa, and A. baumannii demonstrated similar rates of susceptibility to levofloxacin and ciprofloxacin. Susceptibilities to the fluoroquinolones approached or exceeded 90% for all Enterobacteriaceae except Providencia spp. (<= 65%). Approximately 70% of P. aeruginosa and 50% of A. baumanii isolates were susceptible to both fluoroquinolones. Among S. maltophilia isolates, 50% more isolates were susceptible to levofloxacin than to ciprofloxacin. Overall, the rate of ceftazidime nonsusceptibility among Enterobacteriaceae was 8.7%, with fluoroquinolone resistance rates notably higher among ceftazidime-nonsusceptible isolates than ceftazidime-susceptible ones. Multidrug-resistant isolates were present among all species tested but were most prevalent for Klebsiella pneumoniae and Enterobacter cloacae. No gram-negative isolates resistant only to a fluoroquinolone were encountered, regardless of species. Thus, while levofloxacin and ciprofloxacin have maintained potent activity against Enterobacteriaceae, the potential for fluoroquinolone resistance, the apparent association between fluoroquinolone and cephalosporin resistance, and the presence of multidrug resistance in every species examined emphasize the need to maintain active surveillance of resistance patterns among gram-negative bacilli.

* Corresponding author. Mailing address: MRL, 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2500. Fax: (703) 480-2670. E-mail: dsahm{at}mrlinfo.com.

Antimicrobial Agents and Chemotherapy, January 2001, p. 267-274, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.267-274.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gad, G. F., El-Domany, R. A., Zaki, S., Ashour, H. M. (2007). Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother 60: 1010-1017 [Abstract] [Full Text]  
  • Bal, B. S., Haltom, D., Aleto, T., Barrett, M. (2006). Early Complications of Primary Total Hip Replacement Performed with a Two-Incision Minimally Invasive Technique. Surgical Technique. JBJS 88: 221-233 [Abstract] [Full Text]  
  • Karlowsky, J. A., Hoban, D. J., DeCorby, M. R., Laing, N. M., Zhanel, G. G. (2006). Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study.. Antimicrob. Agents Chemother. 50: 2251-2254 [Abstract] [Full Text]  
  • Tumbarello, M., Spanu, T., Sanguinetti, M., Citton, R., Montuori, E., Leone, F., Fadda, G., Cauda, R. (2006). Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome. Antimicrob. Agents Chemother. 50: 498-504 [Abstract] [Full Text]  
  • Putnam, S. D., Sanders, J. W., Tribble, D. R., Rockabrand, D. R., Riddle, M. S., Rozmajzl, P. J., Frenck, R. W. (2005). Posttreatment Changes in Escherichia coli Antimicrobial Susceptibility Rates among Diarrheic Patients Treated with Ciprofloxacin. Antimicrob. Agents Chemother. 49: 2571-2572 [Abstract] [Full Text]  
  • Flamm, R. K., Weaver, M. K., Thornsberry, C., Jones, M. E., Karlowsky, J. A., Sahm, D. F. (2004). Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48: 2431-2436 [Abstract] [Full Text]  
  • Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2004). Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2470 [Abstract] [Full Text]  
  • Bolon, M. K., Wright, S. B., Gold, H. S., Carmeli, Y. (2004). The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant Escherichia coli and Klebsiella pneumoniae May Be Lower than Previously Reported. Antimicrob. Agents Chemother. 48: 1934-1940 [Abstract] [Full Text]  
  • Bravata, D. M., McDonald, K. M., Smith, W. M., Rydzak, C., Szeto, H., Buckeridge, D. L., Haberland, C., Owens, D. K. (2004). Systematic Review: Surveillance Systems for Early Detection of Bioterrorism-Related Diseases. ANN INTERN MED 140: 910-922 [Abstract] [Full Text]  
  • San Gabriel, P., Zhou, J., Tabibi, S., Chen, Y., Trauzzi, M., Saiman, L. (2004). Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 48: 168-171 [Abstract] [Full Text]  
  • Wenzel, R. P., Sahm, D. F., Thornsberry, C., Draghi, D. C., Jones, M. E., Karlowsky, J. A. (2003). In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy. Antimicrob. Agents Chemother. 47: 3089-3098 [Abstract] [Full Text]  
  • Karlowsky, J. A., Jones, M. E., Thornsberry, C., Friedland, I. R., Sahm, D. F. (2003). Trends in Antimicrobial Susceptibilities among Enterobacteriaceae Isolated from Hospitalized Patients in the United States from 1998 to 2001. Antimicrob. Agents Chemother. 47: 1672-1680 [Abstract] [Full Text]  
  • Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Friedland, I. R., Sahm, D. F. (2003). Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47: 1681-1688 [Abstract] [Full Text]  
  • Gesu, G. P., Marchetti, F., Piccoli, L., Cavallero, A. (2003). Levofloxacin and Ciprofloxacin In Vitro Activities against 4,003 Clinical Bacterial Isolates Collected in 24 Italian Laboratories. Antimicrob. Agents Chemother. 47: 816-819 [Abstract] [Full Text]  
  • Karlowsky, J. A., Kelly, L. J., Thornsberry, C., Jones, M. E., Sahm, D. F. (2002). Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of Escherichia coli from Female Outpatients in the United States. Antimicrob. Agents Chemother. 46: 2540-2545 [Abstract] [Full Text]  
  • Masterton, R. G. (2002). Ciprofloxacin resistance--early-warning' signs from the MYSTIC surveillance programme?. J Antimicrob Chemother 49: 218-220 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»